SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Signage outside Genentech's headquarters in Silicon Valley
Business
Genentech Shutters Cancer Immunology Group Amid Wider R&D Reprioritization
The unit’s closure comes as Genentech’s parent Roche rethinks its cancer business, an effort that has included the discontinuation of three early-stage candidates and a T-cell partnership with Adaptimmune.
August 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Website, money and target
Leadership
Leadership Lab: 5 Steps for Building Your Personal Brand
By building and nurturing a strong personal brand, you can benefit in multiple ways, including enhancing your credibility, attracting opportunities and inspiring investor confidence.
August 19, 2024
 · 
5 min read
 · 
Michael Pietrack
FDA headquarters with a purple psychedelic background.
Psychedelics
FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies
Psychedelic drug developers are undeterred by the FDA’s Complete Response Letter for the company’s MDMA therapy for PTSD, and experts expect Lykos will ultimately obtain approval.
August 19, 2024
 · 
5 min read
 · 
Heather McKenzie
A child cups their ear with hand
Gene Therapy
Gene Therapies Break Through Against Genetic Hearing Loss in Children
Regeneron, Akouos and Mass Eye and Ear are testing therapies that can reverse genetic protein deficiency to restore hearing, with promising early results.
August 19, 2024
 · 
5 min read
 · 
Jill Drachenberg
human hearts over an EKG background/
Drug Development
ATTR-CM Space Heats Up as RNA Therapies Show Promise
The entry of new players and new approaches into the ATTR-CM space could help bring down the cost of treatment, experts say.
August 19, 2024
 · 
5 min read
 · 
Aayushi Pratap
President Joe Biden and Vice President Kamala Harris greet guests at the White House celebration of Fourth of July.
Editorial
Medicare Negotiated Drug Prices Are Hollow Victory for Biden, Harris
For the Biden-Harris administration to compare the newly announced negotiated Medicare prices to the list prices for these drugs is, at best, not very meaningful. At worst, it’s disingenuous.
August 16, 2024
 · 
5 min read
 · 
Greg Slabodkin
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Lykos to Slash 75% of Workforce Following FDA Rejection
Lykos will lay off approximately three-quarters of its staff amidst a reorganization aimed at helping the company complete a regulatory resubmission for its MDMA-assisted therapy.
August 16, 2024
 · 
2 min read
 · 
Heather McKenzie
Syringe resting on top of a vaccine vial, with more vaccine bottles in the background
Infectious disease
Pfizer, BioNTech’s Mixed Phase III Data Sets Back COVID-Flu Vaccine Candidate
The companies’ late-stage stumble could allow Moderna to widen its lead, with its mRNA-based combination vaccine eliciting superior immune responses against COVID-19 and three influenza strains.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of AstraZeneca's production plant in Sweden
Regulatory
AstraZeneca’s Imfinzi Scores Lung Cancer Wins With FDA’s NSCLC Approval, SCLC Priority Review
Imfinzi’s perioperative approval comes after both the FDA’s staffers and a panel of external experts expressed concerns about overtreatment when using the PD-L1 blocker both before and after surgery.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS